Latest News

While we enjoy watching the progress our portfolio companies make, we appreciate this does not come easily and requires large measures of expertise, intuition, ingenuity and perseverance. This understanding increases our satisfaction in bringing you news of their accomplishments.

Use the filters above to refine results
29th October 2020

Congratulations to Michael Broxson and team as Q32 Bio close a $60 Million Series B Financing, Advancing Clinical Stage Research in Therapeutics Designed to Restore Immune Homeostasis

29th October 2020

Positive results from Avillion's Phase 2 trial of sonelokinab (M1095) in chronic psoriasis to be presented today in Late-Breaking News Session at EADV 2020 Virtual

27th October 2020

SFJ Pharmaceuticals® partner, Apellis, enters Strategic Collaboration with Sobi to Develop and Commercialize Pegcetacoplan in Hematologic Indications outside the U.S.

26th October 2020

Scorpion Therapeutics debuts with $108M to 'put the sting in cancer'

22nd October 2020

Orbus Therapeutics Expands Series A Financing to $71 Million to Support Ongoing STELLAR Phase 3 Study in Rare Brain Cancer

14th October 2020

NuCana expands its Board of Directors with the Appointment of Abingworth Partner, Bali Muralidhar

9th October 2020

Congratulations Richard, Samir and the team for the successful IPO of Spruce Biosciences on NASDAQ (Ticker: SPRB).

7th October 2020

We are extremely pleased to see Professor Charpentier, co-founder of CRISPR Therapeutics, become a Nobel Laureate

23rd September 2020

Verona Pharma Initiates Phase 3 Clinical Trials with Nebulized Ensifentrine for the Maintenance Treatment of COPD

22nd September 2020

Jasper Therapeutics Doses First Patient in Phase 1 Clinical Trial of JSP191 as Conditioning Agent for Patients with Myelodysplastic Syndromes/Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation

22nd September 2020

NuCana Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares

21st September 2020

Intended Delisting and Cancellation of Ordinary Shares from Trading on AIM

15th September 2020

Tizona Appoints Christine O’Brien as Chief Executive Officer

10th September 2020

AVILLION ANNOUNCES POSITIVE TOP-LINE RESULTS OF PHASE 2 TRIAL OF SONELOKINAB (M1095)

8th September 2020

Verona Pharma Initiates Pilot Study with pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19

6th August 2020

Dicerna Announces Positive Clinical Data for Investigational Treatments RG6346 for Chronic Hepatitis B Virus and Nedosiran for Primary Hyperoxaluria, and Presents Preclinical Data Applying RNAi Technology in New Tissues

27th July 2020

Venatorx Pharmaceuticals Awarded up to $44.2 Million to Advance Novel Inhibitors of Penicillin Binding Proteins targeting WHO Critical Priority Pathogen

22nd July 2020

Nouscom highlights cutting-edge science that led to the design of NOUS-209, a potential off-the-shelf neoantigen cancer vaccine for tumors with Microsatellite Instability

21st July 2020

Gilead Sciences Secures Exclusive Option to Aquire Tizona Therapeutics for $300 Million

17th July 2020

Verona Pharma Raises $200 Million in Oversubscribed Private Placement and Subscription

6th July 2020

Success of the capital increase with pre-emptive subscription rights: €7.3 million raised to finance the Prima System PRIMAvera pivotal study

26th June 2020

Soleno Therapeutics Announces Closing of $57.5 Million Public Offering of Common Stock, Including the Full Exercise of Underwriters’ Option to Purchase Additional Shares

11th June 2020

Vaxcyte Announces Pricing of Upsized Initial Public Offering

8th June 2020

Soleno Therapeutics Announces Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome

27th May 2020

Q32 Bio Launches to Develop Novel Therapeutics Targeting Regulators of Innate and Adaptive Immunity

26th May 2020

Sierra Oncology Appoints Dr. Stephen Dilly as President and Chief Executive Officer

14th May 2020

Verona Pharma Announces FDA Response to End-of-Phase 2 Briefing Package for Ensifentrine in COPD and Outlines Phase 3 ENHANCE Clinical Program

12th May 2020

Spruce Biosciences Announces Launch of CAHstudy.com to Initiate Screening of Patients for CAH Clinical Program

6th May 2020

Spruce Biosciences Strengthens Leadership Team with Appointments of Samir Gharib as CFO and Dasharatha Reddy as VP of Pharmaceutical Development and Manufacturing

4th May 2020

SutroVax Appoints Andrew Guggenhime as Chief Financial Officer and Chief Business Officer

4th May 2020

Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at the American Thoracic Society 2020 International Conference

30th April 2020

eFFECTOR’S Zotatifin demonstrates in vitro Anti-SARS-COV-2 activity in independent international study reported in Peer-reviewed journal Nature

29th April 2020

Venatorx Pharmaceuticals and GARDP Partner to Develop New Antibiotic for Hospital Acquired Infections with Limited Treatment Options

9th April 2020

FirstWave Bio to Initiate Phase 2a/2b Study of FW-1022, a Proprietary Form of Niclosamide, to Treat COVID-19

7th April 2020

Exicure, Inc. Announces Appointment of Timothy P. Walbert as Chairman of the Board

30th March 2020

Verona Pharma Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPD

26th March 2020

SutroVax Announces $110M Series D Financing to Advance Broadest-Spectrum Pneumococcal Vaccine Candidates to Prevent Pneumonia

26th February 2020

Nouscom Strengthens its Management Team

20th February 2020

Spruce Biosciences Raises $88 Million in Series B Financing, co-led by Omega Funds and Abingworth

3rd February 2020

Verona Pharma Announces Senior Management Changes

9th January 2020

eFFECTOR Enters Into Agreement with Pfizer Inc. to Develop Novel First-in-Class Inhibitors of eIF4E to Treat Multiple Cancer Types

9th January 2020

Jasper Therapeutics Announces Expansion of Series A Financing, Bringing Total Corporate Fundraising to More than $50 Million

7th January 2020

Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

6th January 2020

Soleno Therapeutics Completes Target Enrollment in Ongoing DESTINY PWS Phase III Trial of DCCR in Prader Willi Syndrome